Andreas Gerward Discusses Stayble Therapeutics' Breakthrough Product STA363, Market Scope, and Capital Strategy | Andreas Gerward, CEO, Stayble Therapeutic AB. 00:10:00

Share On Facebook Share On Twitter

Andreas has during the last 10 years worked with pharmaceutical development in smaller companies. Since joining Stayble as the CEO in 2014 Andreas has developed the company from selection of the candidate drug through preclinical development and successful clinical trials. Andreas has an engineering background and a master’s in economics and Venture Creation from Chalmers University of Technology.

Recent Videos